Press Releases MaaT Pharma

Equities

MAAT

FR0012634822

Market Closed - Euronext Paris Other stock markets 08:05:14 2024-04-26 am EDT			5-day change	1st Jan Change
9.06 ^EUR	0.00%		+3.90%	+29.80%

Apr. 15	MaaT Pharma: positive data in graft-versus-host disease	CF
Apr. 15	MaaT Pharma Presents Positive 18-Month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MaaT Pharma to Hold Annual General Meeting on May 28, 2024	Apr. 22	BU
Long-term data indicates "significant" potential of aGvHD microbiome treatment	Apr. 15	AQ
MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event	Apr. 15	BU
Advancing microbiome innovation	Apr. 10	AQ
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies	Apr. 08	BU
MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont, Groupe Societe Generale	Apr. 08	AQ
MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont/ Groupe Société Générale	Apr. 05	BU
MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview	Mar. 28	BU
MaaT Pharma Strengthens Executive Team Appointing Jonathan Chriqui as Chief Business Officer	Mar. 21	BU
MaaT Pharma to Present New Preclinical Data at AACR for MaaT034 Aiming To Improve Patients Responses to Immunotherapies	Mar. 20	AQ
MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To improve Patients’ Responses to Immunotherapies	Mar. 19	BU
MaaT Pharma : Inside Information / Other news releases	Mar. 12	PU
MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference	Mar. 12	BU
MaaT Pharma Releases its 2024 Financial Calendar	Mar. 07	BU
MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma	Mar. 06	AQ
MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis	Mar. 01	AQ
MaaT Pharma, Half-year Report on Liquidity Contract with the Brokerage Firm Kepler Cheuvreux	Jan. 23	AQ
MaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase 2b Trial with MaaT033 at ASH 2023	Dec. 12	AQ
ASH 2023: microbiome-based therapy shows potential in graft-versus-host disease	Dec. 11	AQ
MaaT Pharma Announces Two Poster Presentations for MaaT013 and MaaT033 at the Upcoming ASH Conference	Nov. 03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases MaaT Pharma

Equities

MAAT

FR0012634822

Press Releases

Filters